This systematic review and meta-analysis evaluated the safety and efficacy of mesenchymal stem cell (MSC) therapy in adults with acute myocardial infarction (AMI) and ischemic heart failure (IHF). Analyzing 23 clinical trials (11 on AMI and 12 on IHF), the study found that MSC therapy was not associated with acute
